Roche and Nvidia deploy 3,500+ Blackwell GPUs to accelerate AI drug discovery and diagnostics

Roche ramps up AI computing capacity with Nvidia chip expansion

BERLIN, March 16 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab said on Monday it had expanded its artificial intelligence computing capacity with more than 2,100 Nvidia chips to support drug and diagnostics development. Roche said the additional hardware would speed up work across its research and development operations, including modelling, data analysis and clinical trial processes. The drugmaker said ⁠it had deployed 2,176 Nvidia Blackwell graphics processing units (GPUs) across sites in the U.S. and Europe, giving it the largest GPU footprint in the industry. The build-up, which began in 2023, is part of a wider collaboration with Nvidia by Roche, which has been increasing investment in AI tools as large ⁠pharmaceutical groups compete to cut development timelines and reduce costs. "In healthcare, time is the most critical variable," Chief Digital and Technology Officer Wafaa Mamilli said. Drugmakers have announced ⁠a slew of deals for tools to unleash the promise of artificial intelligence, seen as the biggest technological breakthrough since ⁠the internet. Agentic AI, which requires little human intervention, could increase clinical development productivity by about ⁠35% to 45% over the next five years, consultancy McKinsey said last year. Reporting by Maggie Fick, Writing by Friederike Heine; Editing by Alexander Smith Our Standards: The Thomson Reuters Trust Principles., opens new tab

Roche Scales NVIDIA AI Factories Globally to Accelerate Drug Discovery, Diagnostic Solutions and Manufacturing Breakthroughs

Roche is deploying more than 3,500 NVIDIA Blackwell GPUs across hybrid cloud and on‑premises environments in the U.S. and Europe, expanding on an existing collaboration to turn AI and accelerated computing into a core operating capability across its pharmaceutical and diagnostics businesses. At NVIDIA GTC today, Roche unveiled how this new AI computing backbone will power everything from biological foundation models to drug discovery and digital twins for manufacturing. This investment positions Roche with the extensive computing capacity it needs to enable scientists across the enterprise to pursue their most ambitious scientific projects.

Roche ramps up AI computing capacity with Nvidia chip expansion - The Economic Times

Roche said the additional hardware would speed ⁠up ⁠work across its research and development operations, including modelling, data analysis and clinical trial processes.Swiss drugmaker Roche said on Monday it had expanded its artificial intelligence computing capacity with more than 2,100 Nvidia chips to support drug and diagnostics development. Roche said the additional hardware would speed ⁠up ⁠work across its research and development operations, including modelling, data analysis and clinical trial processes. The drugmaker said it had deployed 2,176 Nvidia Blackwell graphics processing units (GPUs) across sites in the U.S. and Europe, giving it the ⁠largest GPU footprint in the industry. The build-up, which began in 2023, is part of ⁠a wider collaboration with Nvidia by Roche, which has been increasing investment in AI tools as large pharmaceutical groups compete to cut development timelines and reduce costs. "In healthcare, time is the most critical variable," Chief Digital and Technology Officer Wafaa Mamilli said. Drugmakers have announced a slew of deals for tools to unleash the promise of ⁠artificial intelligence, seen as the biggest technological breakthrough since the internet. Agentic AI, which requires little human intervention, could increase clinical development productivity by about 35% to 45% over the next five years, consultancy McKinsey said last year.